

Product Data Sheet

Exatecan Intermediate 1

Cat. No.:HY-42487CAS No.:110351-94-5Molecular Formula: $C_{13}H_{13}NO_5$ Molecular Weight:263.25

Target: ADC Cytotoxin

Pathway: Antibody-drug Conjugate/ADC Related

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 2 years

-20°C 1 year

SOLVENT & SOLUBILITY

In Vitro

DMSO: 25 mg/mL (94.97 mM; Need ultrasonic)

| Preparing Stock Solutions | Solvent Mass Concentration | 1 mg | 5 mg | 10 mg |
|------------------------------|-------------------------------|-----------|------------|------------|
| | 1 mM | 3.7987 mL | 18.9934 mL | 37.9867 mL |
| | 5 mM | 0.7597 mL | 3.7987 mL | 7.5973 mL |
| | 10 mM | 0.3799 mL | 1.8993 mL | 3.7987 mL |

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (7.90 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (7.90 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Exatecan Intermediate 1 (compound 6) is an intermediate of Exatecan (DX-8951, HY-13631). Exatecan is an anticancer agent belonging to the class of camptothecin analogs. Exatecan interferes with the proliferation and division of tumor cells by interacting with DNA, thereby inhibiting tumor growth. Exatecan is primarily used for research of a variety of cancers including ovarian, lung and breast cancers^{[1][2]}.

REFERENCES

[1]. Weng W, et al. Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer. Cancer Discov. 2023 Apr 3;13(4):950-973.



Page 2 of 2 www.MedChemExpress.com